NCT02009605

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer.

Detailed description

This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, confirmed at least 28 days following the date of the initial response.

Conditions

• Squamous Cell Carcinoma of Lung

Interventions

Type	Name	Description
DRUG	Icotinib	125mg, oral administration, three times per day.

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-01-01
• Completion: 2016-03-01
• First posted: 2013-12-12
• Last updated: 2015-03-05

Locations

1 site across 1 country: China